Issue Date: July 4, 2016
Moderna wins big Merck investment
Merck & Co. is paying Moderna Therapeutics $200 million in a deal to develop personalized cancer vaccines based on Moderna’s mRNA vaccine technology and Merck’s Keytruda anti-PD-1 cancer therapy. Moderna will use the money to lead the R&D effort and to help build a vaccine manufacturing facility in the Boston area. Moderna made news last year when it raised $450 million in the largest-ever biotech fund-raising. It struck an initial deal with Merck soon thereafter.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society